KMH-233 973B Targeting therapy-resistant prostate cancer via

Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1[J]

Smiles: O=C1NC2=CC=CC=C2N1C1CCN(CC1)C(=O)C1=CC2CCCCCC=2S1

OTX015 is currently in phase I clinical development for oncology indication

2017 Oct 4

116-trimethyl-17-(2-(methylthio)ethyl)-4

KMH-233 973B Targeting therapy-resistant prostate cancer viaKMH 233, a potent, reversible and selective l type amino acid transporter 1 (LAT1) inhibitor, inhibits the uptake of LAT1 substrate, l leucin (IC50=18 M) as well as cell growth. KMH 233 significantly potentiates the efficacy of Bestatin and Cisplatin even at low concentrations (25 M). Product information CAS Number: 1941174 13 5 Molecular Weight: 587. 58 Formula: C32H25N7O5 Chemical Name: (2S) 2 amino 3 {3 [(10,12 dicyano 11 {4